Panacea Biotec Ltd

Panacea Biotec announced the listing of EmulsiPan in the CEPI (Coalition for Epidemic Preparedness Innovations) Library of adjuvants to support the scientific community in advancing vaccine and biotherapeutic development. EmulsiPan has been recognized for its potential in enhancing the efficacy and dose-sparing effects. EmulsiPan is an oil-in-water emulsion adjuvant and is produced by nano-emulsification of squalene along with surfactants and buffers. Squalene is a naturally occurring biodegradable and biocompatible triterpene hydrocarbon found in many plants as well as in humans. EmulsiPan is a ready-to-use sterile emulsion, supplied in a 10 mL USP Type I glass vial for research purposes. It is designed for storage at 2-8'C and maintains stability for over 2-years under recommended conditions. On the occasion, the Chairman and Managing Director, Panacea Biotec, Dr. Rajesh Jain said, 'It is with great pride that we announce the availability of EmulsiPan, a ready-to-use dose sparing adjuvant designed to enhance vaccine efficacy and support global public health initiatives. Such investments showcase our commitment to research and development investments that provide us the edge to not just meet ongoing challenges but also create a future-ready company that is prepared for every possibility and opportunity.' Powered by Capital Market - Live

Net Loss of Panacea Biotec reported to Rs 1.89 crore in the quarter ended March 2025 as against net loss of Rs 1.99 crore during the previous quarter ended March 2024. Sales declined 2.88% to Rs 132.53 crore in the quarter ended March 2025 as against Rs 136.46 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 8.37 crore in the year ended March 2025 as against net loss of Rs 1.17 crore during the previous year ended March 2024. Sales declined 0.01% to Rs 559.09 crore in the year ended March 2025 as against Rs 559.17 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales132.53136.46 -3 559.09559.17 0 OPM %-20.28-4.43 --4.63-3.59 - PBDT-19.333.95 PL -9.132.16 PL PBT-27.75-4.86 -471 -43.94-34.55 -27 NP-1.89-1.99 5 -8.37-1.17 -615 Powered by Capital Market - Live

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live

Net profit of Panacea Biotec reported to Rs 4.52 crore in the quarter ended December 2024 as against net loss of Rs 2.28 crore during the previous quarter ended December 2023. Sales rose 8.63% to Rs 163.49 crore in the quarter ended December 2024 as against Rs 150.50 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales163.49150.50 9 OPM %4.87-0.10 - PBDT10.594.68 126 PBT1.61-4.43 LP NP4.52-2.28 LP Powered by Capital Market - Live

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live

Panacea Biotec announced that the company's wholly owned subsidiary, Panacea Biotec Pharma (PBPL) has launched baby diapers and wipes under the brand name 'NikoMom'. Powered by Capital Market - Live

Panacea Biotec announced that the company's material subsidiary, Panacea Biotec Pharma (PBCL) has made further investment of US$ 9,25,000 (~Rs.7.92 crore) in its wholly owned subsidiary, Panacea Biotec Inc. (PB Inc.) subscription for 9,25,00,000 shares of common stock of PB Inc. at a price of US$ 0.01 per share. Panacea Biotec Inc. being a step-down subsidiary of the company. The investment made by PBPL in WOS is to facilitate the capex and working capital requirements of PB Inc. and is in furtherance of its business. The business of the WOS is in line with the business activities of the Company and PBPL. Powered by Capital Market - Live

The contract is worth $14.95 million (approximately Rs 127 crore). The said order will be executed by calendar year 2025, subject to signing of requisite amendment to the long term arrangement. The project entails supply of bOPV to UNICEF for its requirements in countries in Africa and Asia region as per the orders as may be received from time to time. Panacea Biotec is engaged in the business of research, development, manufacture, and marketing of branded pharmaceutical formulations in India and international markets. The company reported consolidated net loss of Rs 8.29 crore in Q2 FY24 as compared with net profit of Rs 15.70 crore reported in Q2 FY23. Net sales jumped 36.1% YoY to Rs 143.02 crore in Q2 FY24.Powered by Capital Market - Live

Panacea Biotec has received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth ~US$ 14.95 million (~Rs.127 crore) in CY2025.Powered by Capital Market - Live

Net profit of Panacea Biotec reported to Rs 4.71 crore in the quarter ended September 2024 as against net loss of Rs 8.29 crore during the previous quarter ended September 2023. Sales rose 3.03% to Rs 147.35 crore in the quarter ended September 2024 as against Rs 143.02 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales147.35143.02 3 OPM %4.75-2.49 - PBDT10.67-1.24 LP PBT1.99-10.55 LP NP4.71-8.29 LP Powered by Capital Market - Live